BR112023023506A2 - Composições incluindo intensificadores de terapia conjugada - Google Patents

Composições incluindo intensificadores de terapia conjugada

Info

Publication number
BR112023023506A2
BR112023023506A2 BR112023023506A BR112023023506A BR112023023506A2 BR 112023023506 A2 BR112023023506 A2 BR 112023023506A2 BR 112023023506 A BR112023023506 A BR 112023023506A BR 112023023506 A BR112023023506 A BR 112023023506A BR 112023023506 A2 BR112023023506 A2 BR 112023023506A2
Authority
BR
Brazil
Prior art keywords
compositions including
intensifyers
therapy
including conjugation
moiety
Prior art date
Application number
BR112023023506A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard Pracitto
Wieslaw Kazmierski
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of BR112023023506A2 publication Critical patent/BR112023023506A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112023023506A 2021-05-17 2022-05-17 Composições incluindo intensificadores de terapia conjugada BR112023023506A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163189503P 2021-05-17 2021-05-17
PCT/US2022/029533 WO2022245757A1 (en) 2021-05-17 2022-05-17 Compositions including conjugated therapy enhancers

Publications (1)

Publication Number Publication Date
BR112023023506A2 true BR112023023506A2 (pt) 2024-01-30

Family

ID=84140038

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023506A BR112023023506A2 (pt) 2021-05-17 2022-05-17 Composições incluindo intensificadores de terapia conjugada

Country Status (12)

Country Link
US (1) US20240238436A1 (enExample)
EP (1) EP4351658A4 (enExample)
JP (1) JP2024519031A (enExample)
KR (1) KR20240012376A (enExample)
CN (1) CN117295527A (enExample)
AU (1) AU2022277840A1 (enExample)
BR (1) BR112023023506A2 (enExample)
CA (1) CA3219475A1 (enExample)
IL (1) IL307746A (enExample)
MX (1) MX2023013274A (enExample)
PH (1) PH12023553152A1 (enExample)
WO (1) WO2022245757A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069986A1 (en) * 2017-07-26 2019-01-31 Kleo Pharmaceuticals, Inc. Universal abt compounds and uses thereof
EP3773727A4 (en) * 2018-04-09 2022-05-04 Yale University BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS
US10953107B2 (en) * 2018-06-15 2021-03-23 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
JP2023501720A (ja) * 2019-11-18 2023-01-18 クレオ ファーマシューティカルズ， インコーポレイテッド 指向性コンジュゲーション技術
WO2022192478A1 (en) * 2021-03-10 2022-09-15 Biohaven Therapeutics Ltd. Bifunctional degraders of galactose-deficient immunoglobulins
CA3219517A1 (en) * 2021-05-17 2022-11-24 Wieslaw Kazmierski Agents for directed conjugation techniques and conjugated products
US20250108124A1 (en) * 2021-05-19 2025-04-03 Biohaven Therapeutics Ltd. Antibody drug conjugates using mates technology for delivering cytotoxic agents
WO2023043861A2 (en) * 2021-09-16 2023-03-23 Biohaven Therapeutics Ltd. Conjugated antibodies for treating diseases

Also Published As

Publication number Publication date
WO2022245757A1 (en) 2022-11-24
AU2022277840A1 (en) 2023-11-30
CA3219475A1 (en) 2022-11-24
EP4351658A4 (en) 2026-04-15
PH12023553152A1 (en) 2024-03-11
MX2023013274A (es) 2023-11-30
JP2024519031A (ja) 2024-05-08
IL307746A (en) 2023-12-01
EP4351658A1 (en) 2024-04-17
KR20240012376A (ko) 2024-01-29
CN117295527A (zh) 2023-12-26
US20240238436A1 (en) 2024-07-18
AU2022277840A9 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
BR112023023527A2 (pt) Inibidores de nlrp3
BR112021026009A2 (pt) Composições líquida e farmacêutica, conjugados dos análogos de tubulisina, análogo de tubulisina, agentes de ligação celular e sinérgico, e, célula tumoral
BR112022016412A2 (pt) Composições e método de deslignificação de biomassa vegetal ou material de biomassa
MX2022010515A (es) Conjugacion mediada por transglutaminasa.
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
BR112022002720A2 (pt) Formulações de conjugados de benzazepinas e usos das mesmas
AR123569A1 (es) Conjugados de pirrolobenzodiazepina-anticuerpo y usos de los mismos
BR112022003046A8 (pt) Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t
BR112022003982A2 (pt) Compostos heterocíclicos
BR112022018828A2 (pt) Derivados de benzodiazepina como gaba a gamma1 pams
BR112021019957A2 (pt) Azinas condensadas para modulação de ep300 ou cbp e indicações da mesma
BR112023023506A2 (pt) Composições incluindo intensificadores de terapia conjugada
CO2023012358A2 (es) Conjugados de amatoxina y anticuerpo específicos de linfocitos b
CL2022001323A1 (es) Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x
BR112023027025A2 (pt) Métodos de uso de inibidores da aldosterona sintase
CO2023010985A2 (es) Composiciones adhesivas que comprenden adhesivos de base biológica a partir de recursos renovables, y su uso para la fabricación de madera contrachapada
BR112018070480A2 (pt) composto da fórmula, processo para fabricar o composto da fórmula, mistura, uso do composto da fórmula, e, composição em gel
BR112023026735A2 (pt) Conjugado, composto de conector-fármaco, uso de um composto de conector-fármaco, e, composição farmacêutica
BR112022015505A2 (pt) Composições e métodos para tratar doença de pompe
MX2025003004A (es) Formas farmaceuticas de un inhibidor de cd73
MX2024012970A (es) Inhibidores de la 17-beta-hidroxiesteroide deshidrogenasa tipo 13 que contienen pirimidinona
MX2024011654A (es) Formulaciones que comprenden melfalan flufenamida y ciclodextrina
BR112023002346A2 (pt) Imunoconjugados direcionados a cd46 e métodos de uso dos mesmos
BR112023026272A2 (pt) Combinação, composição farmacêutica, e, kit de partes
BR112023000700A2 (pt) Compostos, composições e usos de éster de fosfato de poliéter